Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy-Protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Impact of Physician-staffed Helicopters on Pre-hospital Patient Outcomes: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Hypothermic to ischemic ratio and mortality in post-cardiac arrest patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Response letter to comments made by J. G. Förster, M. Pitkänen

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. APACHE II score validation in emergency abdominal surgery. A post hoc analysis of the InCare trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Endothelial glycocalyx shedding in patients with burns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: In Europe 700.000 new cases of sepsis occur annually and more than 100.000 of these patients die due to multiorgan failure (MOF). We have identified shock-induced endotheliopathy (SHINE) to be associated with development of MOF and mortality. Furthermore, in patients with septic shock those with circulating levels of thrombomodulin (TM) above 10 ng/mL have twice the mortality (56% vs 28%) than those with levels below this level. Pilot studies indicate that infusion of iloprost (1 ng/kg/min) is associated with improved endothelial function in patients with septic shock.

MATERIAL AND METHODS: This is a multicenter, randomized, blinded, investigator-initiated, adaptive phase 2B trial in up to 384 patients with septic shock-induced endotheliopathy defined by TM > 10 ng/mL who are allocated 1:1 to 72 hours continuous infusion of iloprost 1 ng/kg/min or placebo (equal volume of saline). The primary outcome is the mean daily modified Sequential Organ Failure Assessment (SOFA) score in the ICU up to day 90. Secondary outcomes include 28- and 90-day all-cause mortality, days alive without vasopressor in the ICU within 90 days, days alive without mechanical ventilation in the ICU within 90 days, days alive without renal replacement therapy in the ICU within 90 days, numbers of serious adverse reactions, and the number of serious adverse events within the first 7 days.

DISCUSSION: This trial tests the safety and efficacy of iloprost vs placebo for 72 hours in patients with septic shock and SHINE. The outcome measures focus on the potential effect of the intervention to mitigate organ failure.

TRIAL REGISTRATION: COMBAT-SHINE trial-EudraCT no. 2019-001131-31-Clinicaltrials.gov: NCT04123444-Ethics Committee no. H-19018258.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
Vol/bind64
Udgave nummer5
Sider (fra-til)705-711
Antal sider7
ISSN0001-5172
DOI
StatusUdgivet - maj 2020

ID: 59030640